Global Health Press

Category - GHP News

Literature update ViVa week 19-2026

1. Australia’s child flu vaccine slide is the real post-COVID warning This multicenter prospective test-negative surveillance study enrolled 8,762 influenza-positive hospitalizations and 10,955 influenza-negative...

Vaccines and Vaccination (ViVa) 19 news

Asia (SE Asia, China, India) No new schedule or policy updates from CDC-equivalents this week. We found no fresh national immunization schedule changes or formal vaccine-policy statements from CDC-equivalent agencies in...

Literature update ViVa week 18-2026

1. MenB vaccines show lab cross-protection against MenX—but conjugates are still the gold standard In this laboratory study, investigators evaluated whether the protein-based meningococcal B vaccines 4CMenB (Bexsero)...

Literature update ViVa week 17-2026

1. Multistage malaria shot shows mid-term protection in Malian adults – but transmission benefits still unproven In this randomized, double blind trial from peri urban Mali, 34 healthy adults (18–50 years) with...

Why this history matters now

The story of early TBE research in the Soviet Union is more than a historical curiosity. It offers a vivid case study of how science, politics, and social conditions intertwine. It reminds us that medical breakthroughs...

Vaccines and Vaccination (ViVa) news

Over roughly the past week, formal NITAG/agency outputs have largely reinforced and operationalized earlier 2026 policy decisions, while the most clearly “new” developments sit in World/Regional Immunization Week...

Literature update ViVa week 16-2026

1. MF59-aQIV looks economically persuasive in Korea and Taiwan — but the price assumptions do a lot of the work This modelling study assessed the cost-effectiveness of MF59-adjuvanted quadrivalent influenza vaccine...